Bioline Rx traded at $0.70 this Wednesday December 7th, increasing $0.02 or 2.93 percent since the previous trading session. Looking back, over the last four weeks, Bioline Rx gained 12.51 percent. Over the last 12 months, its price fell by 70.22 percent. Looking ahead, we forecast Bioline Rx to be priced at 0.69 by the end of this quarter and at 0.63 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Arca Biopharma 2.12 0.02 0.79% -9.55%
Bioline Rx 0.70 0.02 2.93% -70.22%
Bluebird Bio 7.80 -0.04 -0.45% -22.05%
Bio Path 1.49 -0.05 -2.94% -69.94%
Capricor Therapeutics 4.07 -0.01 -0.25% 23.33%
Idera Pharmaceuticals 0.31 0.002 0.53% -63.19%
Iveric bio Inc. 21.14 0 0% 42.93%

Indexes Price Day Year
USND 10979 -36.28 -0.33% -30.46%

Bioline Rx
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.